Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin

Ovarian clear cell carcinoma (OCCC) has an aggressive histology. Our aim was to evaluate the progression free survival (PFS) of OCCC patients compared to other epithelial histology patients when treated with surgery followed by carboplatin and paclitaxel (PT) regimen. The medical records of them who...

Full description

Saved in:
Bibliographic Details
Main Authors: Daranee Sirichaisutdhikorn, Prapaporn Suprasert, Surapan Khunamornpong
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956646797&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/48917
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-48917
record_format dspace
spelling th-cmuir.6653943832-489172018-08-16T02:16:00Z Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin Daranee Sirichaisutdhikorn Prapaporn Suprasert Surapan Khunamornpong Biochemistry, Genetics and Molecular Biology Medicine Ovarian clear cell carcinoma (OCCC) has an aggressive histology. Our aim was to evaluate the progression free survival (PFS) of OCCC patients compared to other epithelial histology patients when treated with surgery followed by carboplatin and paclitaxel (PT) regimen. The medical records of them who treated with PT regimen at Chiang Mai University Hospital between January 2004 and December 2008 were reviewed. 67 ovarian clear cell patients were compared to 121 non-clear cell ovarian cancer patients. The mean age of OCCC patients was younger than that of the non-clear cell group (46.7 vs. 51.2 years old, P=0.001). OCCC patients presented in early stage more often than the non-clear cell group (76.1% vs. 38.0%, P=0.001). The surgical procedures in both groups were not significantly different. The complete response rates of OCCC patients and other epithelial histology patients were 65.7% and 55.3%, respectively (P=0.01). With a mean follow-up time of 25 months, the 3-year PFS rates of OCCC and non-clear cell patients in early stages were not significantly different (65.4% vs. 64.2%, P=0.45). However, in the advanced stage, the 1-year PFS rate of OCCC patients was significantly lower than that of non clear cell patients (6.3% vs. 49.6%, P=0.001). In conclusion, patients were commonly younger and presented in earlier stages than non-clear cell ovarian cancer patients. In early stages, clear cell ovarian cancer patients had similar outcomes to other epithelial ovarian histology patients, whereas the outcome was very poor in advanced stages. 2018-08-16T02:06:37Z 2018-08-16T02:06:37Z 2009-01-01 Journal 2476762X 15137368 2-s2.0-77956646797 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956646797&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/48917
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Biochemistry, Genetics and Molecular Biology
Medicine
spellingShingle Biochemistry, Genetics and Molecular Biology
Medicine
Daranee Sirichaisutdhikorn
Prapaporn Suprasert
Surapan Khunamornpong
Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
description Ovarian clear cell carcinoma (OCCC) has an aggressive histology. Our aim was to evaluate the progression free survival (PFS) of OCCC patients compared to other epithelial histology patients when treated with surgery followed by carboplatin and paclitaxel (PT) regimen. The medical records of them who treated with PT regimen at Chiang Mai University Hospital between January 2004 and December 2008 were reviewed. 67 ovarian clear cell patients were compared to 121 non-clear cell ovarian cancer patients. The mean age of OCCC patients was younger than that of the non-clear cell group (46.7 vs. 51.2 years old, P=0.001). OCCC patients presented in early stage more often than the non-clear cell group (76.1% vs. 38.0%, P=0.001). The surgical procedures in both groups were not significantly different. The complete response rates of OCCC patients and other epithelial histology patients were 65.7% and 55.3%, respectively (P=0.01). With a mean follow-up time of 25 months, the 3-year PFS rates of OCCC and non-clear cell patients in early stages were not significantly different (65.4% vs. 64.2%, P=0.45). However, in the advanced stage, the 1-year PFS rate of OCCC patients was significantly lower than that of non clear cell patients (6.3% vs. 49.6%, P=0.001). In conclusion, patients were commonly younger and presented in earlier stages than non-clear cell ovarian cancer patients. In early stages, clear cell ovarian cancer patients had similar outcomes to other epithelial ovarian histology patients, whereas the outcome was very poor in advanced stages.
format Journal
author Daranee Sirichaisutdhikorn
Prapaporn Suprasert
Surapan Khunamornpong
author_facet Daranee Sirichaisutdhikorn
Prapaporn Suprasert
Surapan Khunamornpong
author_sort Daranee Sirichaisutdhikorn
title Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
title_short Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
title_full Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
title_fullStr Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
title_full_unstemmed Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
title_sort clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956646797&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/48917
_version_ 1681423316396539904